Publications by authors named "J D Ostrow"
Introduction/aims: Higher urate levels are associated with improved ALS survival in retrospective studies, however whether raising urate levels confers a survival advantage is unknown. In the Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (SURE-ALS) trial, inosine raised serum urate and was safe and well-tolerated. The SURE-ALS2 trial was designed to assess longer term safety.
View Article and Find Full Text PDFArticle Synopsis
- Coformulated sodium phenylbutyrate/taurursodiol (PB/TURSO) has been shown to extend survival and slow decline in amyotrophic lateral sclerosis (ALS) patients.
- The CENTAUR trial aimed to assess whether PB/TURSO improved survival without the need for tracheostomy or ventilation and reduced the occurrence of first hospitalizations.
- Results indicated that patients treated with PB/TURSO had a 47% lower risk of key health events like death or needing ventilation compared to those on placebo, highlighting its potential benefits for ALS management.
Vaccines stimulate various immune factors critical to protective immune responses. However, a comprehensive picture of vaccine-induced immune factors and pathways have not been systematically collected and analyzed. To address this issue, we developed VaximmutorDB, a web-based database system of vaccine immune factors (abbreviated as "vaximmutors") manually curated from peer-reviewed articles.
View Article and Find Full Text PDFAn orally administered, fixed-dose coformulation of sodium phenylbutyrate-taurursodiol (PB-TURSO) significantly slowed functional decline in a randomized, placebo-controlled, phase 2 trial in ALS (CENTAUR). Herein we report results of a long-term survival analysis of participants in CENTAUR. In CENTAUR, adults with ALS were randomized 2:1 to PB-TURSO or placebo.
View Article and Find Full Text PDFBackground: Sodium phenylbutyrate and taurursodiol have been found to reduce neuronal death in experimental models. The efficacy and safety of a combination of the two compounds in persons with amyotrophic lateral sclerosis (ALS) are not known.
Methods: In this multicenter, randomized, double-blind trial, we enrolled participants with definite ALS who had had an onset of symptoms within the previous 18 months.